Hypertension News and Research RSS Feed - Hypertension News and Research

Chronic hypertension increases glaucoma risk

Chronic hypertension increases glaucoma risk

A new study published in Investigative Ophthalmology & Visual Science has found that chronic (long term) hypertension increases a person's susceptibility to glaucoma. These results suggest that doctors should consider a patient's blood pressure levels in managing the potentially blinding eye disorder. [More]
Stress can trigger diabetes, depression and other autoimmune diseases

Stress can trigger diabetes, depression and other autoimmune diseases

Stress is an ability of humans to fight or flee when faced with problems affecting the individual. By changes in the organism, adaptation to various physical conditions is achieved: burns, bruises, bleeding or psychosocial traumas. [More]
Combination of bedaquiline and verapamil reduces side effects, improves outcomes for TB patients

Combination of bedaquiline and verapamil reduces side effects, improves outcomes for TB patients

While an effective treatment is available for combating multidrug-resistant tuberculosis, it carries serious side effects for patients. [More]
FDA approves Hospira's Dyloject (diclofenac sodium) Injection for pain management

FDA approves Hospira's Dyloject (diclofenac sodium) Injection for pain management

Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, has received approval from the U.S. Food and Drug Administration for Dyloject (diclofenac sodium) Injection, a proprietary nonsteroidal anti-inflammatory drug (NSAID) analgesic. [More]
Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen, Gilead to jointly develop darunavir-based, single-tablet regimen for HIV treatment

Janssen R&D Ireland announced today an amendment to its existing agreement with Gilead Sciences, Inc., initially established in 2011, for the development of a once daily, darunavir-based, single-tablet regimen (STR) for the treatment of people living with HIV. [More]
United Therapeutics submits pre-market approval application for use of Remodulin with implantable drug infusion system

United Therapeutics submits pre-market approval application for use of Remodulin with implantable drug infusion system

United Therapeutics Corporation (NASDAQ: UTHR) announced today that Medtronic, Inc. (NYSE: MDT) has submitted a pre-market approval application to the U.S. Food and Drug Administration (FDA) for the use of Medtronic's SynchroMed® II implantable drug infusion system (including a newly developed catheter) for use with United Therapeutics' Remodulin® (treprostinil) Injection delivered intravenously to patients with pulmonary arterial hypertension. [More]
FDA approves Novo Nordisk’s weight loss injection, Saxenda

FDA approves Novo Nordisk’s weight loss injection, Saxenda

Novo Nordisk today announced that the Food and Drug Administration (FDA) has approved the new drug application (NDA) for Saxenda® (liraglutide [rDNA origin] injection), the first once-daily glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management. [More]
Actavis receives complete response letter for nebivolol/valsartan FDC for treatment of hypertension

Actavis receives complete response letter for nebivolol/valsartan FDC for treatment of hypertension

Actavis plc today confirmed that the Company has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for the fixed-dose combination (FDC) of nebivolol and valsartan for the treatment of hypertension. [More]
Medical researchers at Saint Louis University bring hope to those in pain and sickness

Medical researchers at Saint Louis University bring hope to those in pain and sickness

This year, Saint Louis University medical researchers advanced their fields, contributing to human knowledge and bringing hope to those in pain and sickness. [More]
Multicenter, clinical trial to address long-term complications in CKD patients

Multicenter, clinical trial to address long-term complications in CKD patients

in collaboration with Parkland Health and Hospital System, Texas Health Resources, VA North Texas Health Care System, and ProHealth Physicians, Inc. of Connecticut - will lead the first National Institutes of Health-funded, multicenter, clinical trial to address interventions for patients with multiple chronic conditions centered around kidney disease. [More]
FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

FDA approves AbbVie's VIEKIRA PAK for treatment of patients with GT1 HCV infection

The U.S. Food and Drug Administration has approved AbbVie's VIEKIRA PAK, an all-oral, interferon-free treatment, with or without ribavirin (RBV), for the treatment of patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection, including those with compensated cirrhosis. [More]
Long-term axitinib in RCC effective with ‘controllable’ toxicities

Long-term axitinib in RCC effective with ‘controllable’ toxicities

Axitinib treatment is effective in the long-term in Japanese patients with metastatic renal cell carcinoma and has manageable toxicity, a phase II study suggests. [More]
Study: Older adults with high blood pressure appear to have good kidney health after donation

Study: Older adults with high blood pressure appear to have good kidney health after donation

With proper monitoring, kidney donation may be safe for individuals with high blood pressure, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology. The study found that while hypertension can have negative effects on the kidneys, older adults with the condition appear to have good kidney health following donation. [More]
Researchers examining new antioxidant-based therapeutic approaches to hypertension

Researchers examining new antioxidant-based therapeutic approaches to hypertension

High blood pressure affects more than 70 million Americans and is a major risk factor for stroke, heart failure and other renal and cardiovascular diseases. Two University of Houston College of Pharmacy researchers are examining the role of intrinsic antioxidant pathways in mitigating hypertension. [More]
Lilly receives FDA approval for CYRAMZA (ramucirumab)

Lilly receives FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its third U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). [More]
CVRx receives HDE approval for Barostim neo legacy device

CVRx receives HDE approval for Barostim neo legacy device

CVRx, Inc., a privately held medical device company, announced today that it has received Humanitarian Device Exemption (HDE) approval from the U.S. Food and Drug Administration for its Barostim neo legacy device. [More]
ARA 290 drug reduces neuropathic pain in type 2 diabetic patients

ARA 290 drug reduces neuropathic pain in type 2 diabetic patients

Molecular Medicine, a peer-reviewed biomedical journal published by the Feinstein Institute Press, published the results of a new study reporting clinically significant pain reduction in type 2 diabetic patients. In an exploratory study conducted by Araim Pharmaceuticals, a biotech company developing novel treatments for chronic diseases, investigators also observed improvements in metabolic control in patients administered ARA 290. [More]
Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Novartis announced today that the US Food and Drug Administration has approved Signifor long-acting release (LAR) (pasireotide) for injectable suspension, for intramuscular use, for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. [More]
Deoxygenated hemoglobin triggers conversion of nitrite to nitric oxide

Deoxygenated hemoglobin triggers conversion of nitrite to nitric oxide

Understanding how nitrite can improve conditions such as hypertension, heart attack and stroke has been the object of worldwide research studies. New research from Wake Forest University has potentially moved the science one step closer to this goal. [More]
IRCM researchers uncover mechanism that regulates dopamine levels in the brain

IRCM researchers uncover mechanism that regulates dopamine levels in the brain

Researchers in Montréal led by Jacques Drouin, D.Sc., uncovered a mechanism regulating dopamine levels in the brain by working on a mouse model of late onset Parkinson's disease. [More]